Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukaemia: Final 5-year results from the BFORE trial Meeting Abstract
| Authors: | Milojkovic, D.; Brümmendorf, T. H.; Cortes, J. E.; Gambacorti-Passerini, C.; Clark, R. E.; Le Coutre, P.; García-Gutierrez, V.; Chuah, C.; Kota, V.; Lipton, J. H.; Rousselot, P. H.; Mauro, M. J.; Hochhaus, A.; Monroy, R. H.; Leip, E.; Purcell, S.; Yver, A.; Viqueira, A.; Deininger, M. W. |
| Abstract Title: | Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukaemia: Final 5-year results from the BFORE trial |
| Meeting Title: | 62nd Annual Scientific Meeting of the British Society for Haematology |
| Journal Title: | British Journal of Haematology |
| Volume: | 197 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Apr 3-5 |
| Meeting Location: | Manchester, United Kingdom |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2022-04-01 |
| Start Page: | 23 |
| End Page: | 25 |
| Language: | English |
| ACCESSION: | WOS:000776484300023 |
| PROVIDER: | wos |
| PUBMED: | 35362090 |
| DOI: | 10.1111/bjh.18132 |
| Notes: | Meeting Abstract: BSH22-OR16 -- Hybrid meeting, also held virtually -- Source: Wos |
